<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395563</url>
  </required_header>
  <id_info>
    <org_study_id>GermanCRC</org_study_id>
    <nct_id>NCT01395563</nct_id>
  </id_info>
  <brief_title>Strength Training on Pancreatic Cancer</brief_title>
  <acronym>STOPC</acronym>
  <official_title>Strength Training on Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether prednisone, methotrexate, and
      cyclophosphamide are effective in the treatment of rapidly progressive hearing loss in both
      ears due to autoimmune inner ear disease (AIED).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden out-of-hospital cardiac arrest (OOH-CA) remains a significant cause of death, in spite
      of recent declines in overall mortality from cardiovascular disease. Existing methods of
      emergency resuscitation are inadequate due to time delays inherent in the transport of a
      trained responder with defibrillation capabilities to the side of the OOH-CA victim. Existing
      Emergency Medical Services (EMS) systems typically combine paramedic Emergency Medical
      Technician (EMT) services with some level of community involvement, such as bystander
      cardiopulmonary resuscitation (CPR) training. Some communities include automated external
      defibrillators (AEDs) at isolated sites or in mobile police or fire vehicles. A
      comprehensive, integrated community approach to treatment with AEDs would have community
      units served by these volunteer non-medical responders who can quickly identify and treat a
      patient with OOH-CA. Such an approach is termed Public Access Defibrillation (PAD).
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle mass and strength</measure>
    <time_frame>after 8 weeks of intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>after 8 weeks of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Cachexia</condition>
  <condition>Myopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pancreatic cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pancreatic cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>strength training</intervention_name>
    <description>strength training, high intensity, twice up to 3 times per week</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>progressive resistance training</other_name>
    <other_name>sports</other_name>
    <other_name>muscle hypertrophia</other_name>
    <other_name>cachexia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with pancreatic carcinomas after surgery (resection or exploration)

          -  given consent

        Exclusion Criteria:

          -  acute infection

          -  pain

          -  no mobility or ability for walking or standing

          -  severe neurological disorders (apoplex, morbus Parkinson, paresis of the lower
             extremeties)

          -  severe cardiac or cardiovascular diseases (z.B. heart insufficiency NYHA III,
             myocardial infarction &lt;3 months)

          -  rhytmical disorders, that contraindicate ergospirometric examinations

          -  cardiac therapy with digitalis pharmacy

          -  unclear syncopes

          -  severe pulmonal insufficiency

          -  renal insufficiency (GFR &lt; 30% at Krea &gt;3 mg/dl)

          -  synchronous participation in an other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Werner, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holger Krakowski-Roosen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German CRC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Martignoni, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Pancreas Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Cancer Research Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <name_title>Krakowski-Roosen, Dr.</name_title>
    <organization>German Cancer Research Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

